NFJ Investment Group LLC Has $16.17 Million Stock Holdings in Johnson & Johnson $JNJ

Key Points

• NFJ Investment Group LLC increased its stake in Johnson & Johnson by 30.9%, owning 97,511 shares worth approximately $16.17 million as of the last quarter.
• Johnson & Johnson reported a quarterly earnings of $2.77 per share, surpassing estimates, with revenues reaching $23.74 billion and a year-over-year growth of 5.8%.
• The company declared a quarterly dividend of $1.30, reflecting an annualized rate of $5.20, resulting in a dividend yield of 2.9%.

NFJ Investment Group LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 30.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 97,511 shares of the company's stock after purchasing an additional 23,012 shares during the quarter. NFJ Investment Group LLC's holdings in Johnson & Johnson were worth $16,171,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Highline Wealth Partners LLC boosted its stake in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the first quarter worth $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson in the first quarter worth $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter worth $49,000. Finally, Capital A Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth $50,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded down $0.57 during trading on Friday, reaching $178.20. The company's stock had a trading volume of 9,733,095 shares, compared to its average volume of 7,556,979. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The business's fifty day moving average price is $168.57 and its 200-day moving average price is $160.78. The firm has a market cap of $429.15 billion, a price-to-earnings ratio of 19.06, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson & Johnson's payout ratio is presently 55.61%.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Morgan Stanley lifted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. UBS Group lifted their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Wall Street Zen cut Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Friday. Finally, Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $176.29.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.